-+ 0.00%
-+ 0.00%
-+ 0.00%

KYMERA THERAPEUTICS INC - KT-621 BROADEN2 PHASE 2B ATOPIC DERMATITIS TRIAL ONGOING, DATA EXPECTED BY MID-2027

Reuters·04/13/2026 11:00:01

Please log in to view news